Cyclooxygenase in biology and disease
- PMID: 9737710
Cyclooxygenase in biology and disease
Abstract
Cyclooxygenase (COX), the key enzyme required for the conversion of arachidonic acid to prostaglandins was first identified over 20 years ago. Drugs, like aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. In the past decade, however, more progress has been made in understanding the role of cyclooxygenase enzymes in biology and disease than at any other time in history. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Here, we summarize the current understanding of the role of cyclooxygenase-1 and -2 in different physiological situations and disease processes ranging from inflammation to cancer. We have attempted to include all of the most relevant material in the field, but due to the rapid progress in this area of research we apologize that certain recent findings may have been left out.
Comment in
-
From molecular analysis to medical practice: recent studies reveal new therapeutic _targets for an old medicine.FASEB J. 1998 Sep;12(12):1061. doi: 10.1096/fasebj.12.12.1061. FASEB J. 1998. PMID: 9737709 No abstract available.
Similar articles
-
Cyclooxygenase-2: a therapeutic _target.Annu Rev Med. 2002;53:35-57. doi: 10.1146/annurev.med.53.082901.103952. Annu Rev Med. 2002. PMID: 11818462 Review.
-
Regulation of cyclo-oxygenase-2.Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):787-800. doi: 10.1053/bega.2001.0235. Best Pract Res Clin Gastroenterol. 2001. PMID: 11566041 Review.
-
Distribution of COX-1 and COX-2 in normal and inflamed tissues.Adv Exp Med Biol. 1997;400A:167-70. doi: 10.1007/978-1-4615-5325-0_24. Adv Exp Med Biol. 1997. PMID: 9547553
-
Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors.Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):291-8. doi: 10.1358/mf.2000.22.5.796648. Methods Find Exp Clin Pharmacol. 2000. PMID: 11031730 Review.
-
Dual acting anti-inflammatory drugs: a reappraisal.Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872. Pharmacol Res. 2001. PMID: 11735348 Review.
Cited by
-
TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells.Cancer Res Treat. 2015 Jan;47(1):101-9. doi: 10.4143/crt.2013.192. Epub 2014 Oct 22. Cancer Res Treat. 2015. PMID: 25544576 Free PMC article.
-
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.Pharmacogenet Genomics. 2013 Aug;23(8):428-437. doi: 10.1097/FPC.0b013e3283631784. Pharmacogenet Genomics. 2013. PMID: 23778325 Free PMC article. Clinical Trial.
-
Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs.Dig Dis Sci. 2006 Jan;51(1):168-72. doi: 10.1007/s10620-006-3103-5. Dig Dis Sci. 2006. PMID: 16416231
-
Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?Int Urol Nephrol. 2008;40(2):295-301. doi: 10.1007/s11255-007-9268-9. Int Urol Nephrol. 2008. PMID: 17899436
-
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.Mol Vis. 2007 Apr 30;13:677-91. Mol Vis. 2007. PMID: 17563718 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous